Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akoya Biosciences, Inc.

1.26
-0.0400-3.08%
Post-market: 1.260.00000.00%17:31 EDT
Volume:106.89K
Turnover:136.50K
Market Cap:62.84M
PE:-1.31
High:1.31
Open:1.31
Low:1.25
Close:1.30
Loading ...
Feb 25, 2025

Business Combinations

Form 425 - Prospectuses and communications, business combinations
Feb 25, 2025

Major Issues Report

Form 8-K - Current report
Feb 25, 2025

Business Combinations

Form 425 - Prospectuses and communications, business combinations
Feb 11, 2025

Business Combinations

Form 425 - Prospectuses and communications, business combinations
Jan 16, 2025

Business Combinations

Form 425 - Prospectuses and communications, business combinations
Jan 16, 2025

Business Combinations

Form 425 - Prospectuses and communications, business combinations
Jan 15, 2025

Business Combinations

Form 425 - Prospectuses and communications, business combinations
Jan 14, 2025

Business Combinations

Form 425 - Prospectuses and communications, business combinations
Jan 10, 2025

Business Combinations

Form 425 - Prospectuses and communications, business combinations
Jan 10, 2025

Business Combinations

Form 425 - Prospectuses and communications, business combinations
Jan 10, 2025

Major Issues Report

Form 8-K - Current report
Jan 10, 2025

Business Combinations

Form 425 - Prospectuses and communications, business combinations
Jan 10, 2025

Business Combinations

Form 425 - Prospectuses and communications, business combinations
Dec 13, 2024

Major Issues Report

Form 8-K - Current report
Nov 15, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 15, 2024

Major Issues Report

Form 8-K - Current report
Nov 04, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Oct 04, 2024

Major Issues Report

Form 8-K - Current report
Aug 28, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Aug 06, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]